MHRA approves Phase I/II clinical trial of IN3BIO vaccine for colorectal cancer patients
March 10, 2022Business Services
The MHRA has approved a Phase I/II clinical trial of IN3BIO’s colorectal cancer vaccine. This is the company’s second global …
Vicore adds to rare lung disease pipeline with PAH indication
March 9, 2022Research and Development
Vicore Pharma has announced plans to initiate a clinical trial with C21 in pulmonary arterial hypertension (PAH).
NICE draft guidance does not recommend pembrolizumab plus chemo for triple negative breast cancer
March 9, 2022Research and Development
Draft guidance published by NICE for public consultation does not recommend pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) for …
Omicron sub-variant BA.2 makes up 11.6% of COVID-19 variants in US
March 9, 2022Research and Development
The CDC said that the BA.2 sub-variant of Omicron is estimated to be 11.6% of the coronavirus variants circulating in …
MHRA authorisation of new treatment for chronic kidney disease associated with diabetes
March 9, 2022Research and Development
The MHRA has authorised the use of Kerendia® (finerenone) (10mg or 20mg), an oral, first-in-class non-steroidal, selective mineralocorticoid receptor (MR) …
Moderna announces its global public health strategy
March 8, 2022Moderna has announced its global public health strategy through four new initiatives which aim to advance mRNA vaccines for the …
Study may see end of need for invasive endometriosis diagnosis surgery
March 8, 2022Manufacturing and Production
A new study of women living with endometriosis is underway, exploring the potential of Artificial intelligence (AI), and cutting-edge medical …
Neuraxpharm expands in Southeast Europe
March 8, 2022Manufacturing and Production
Neuraxpharm Group have announced the expansion of its business in Southeast Europe, through the acquisition of Brain Therapeutics, a company …
Major US study finds COVID-19 vaccines not linked to deaths
March 8, 2022Manufacturing and Production
A study into vaccine side-effects, based in the US, has found no link between two COVID-19 jabs and the number …
Malaysia to receive Pfizer’s COVID-19 pills in two weeks, says Health Minister
March 7, 2022Sales and Marketing
Khairy Jamaluddin, Health Minister of Malaysia, has shared that the country expects to receive its first shipment of Pfizer’s oral …
HUTCHMED receives $15 million to begin Phase III study of lung cancer treatment
March 7, 2022Sales and Marketing
HUTCHMED has received $15 million from AstraZeneca, for the initiation of start-up activities for SAFFRON, the first global Phase III …
AbbVie acquires Syndesi Therapeutics
March 7, 2022Sales and Marketing
Syndesi Therapeutics has been acquired by AbbVie in a deal worth a potential $1 billion.Syndesi was created in 2018 as …
India: approval for drug treating CKD-associated anaemia
March 7, 2022Sales and Marketing
Zydus Lifesciences received approval from the Drugs Controller General of India (DCGI) for its new drug application for Oxemia (Desidustat). …
Phase III trial into nirsevimab for RSV treatment yields positive results
March 4, 2022Medical Communications
The latest results from Sanofi and AstraZeneca’s Phase III trial nirsevimab support the vaccine’s ability to protect all infants from …
Median Technologies iBiopsy Lung Cancer Screening Software
March 4, 2022Medical Communications
Median Technologies has announced that the company has filed a regulatory submission to the FDA for its iBiopsy Lung Cancer …
Promising treatment targeting 40% mortality Candida infection
March 4, 2022Medical Communications
A Promising Innovation Medicine (PIM) designation has been awarded to rezafungin by the MHRA, for the treatment of invasive candidiasis. …
Anti-inflammatory baricitinib is a life-saving COVID-19 drug
March 4, 2022Medical Communications
UK experts say they have identified another life-saving drug that can alleviate COVID-19 illness. The anti-inflammatory baricitinib is usually used …
Risk of hospitalisation five times higher with J&J
March 3, 2022Business Services, Medical Communications
A study published in Jama Network Open has revealed that Johnson & Johnson’s coronavirus vaccine was far less effective at …
FDA grants breakthrough therapy designation to RSV vaccine
March 3, 2022Business Services, Medical Communications
The FDA has granted a Breakthrough Therapy Designation to Pfizer’s respiratory syncytial virus (RSV) vaccine candidate, for the prevention of …
WHO recommends Merck’s COVID-19 pill
March 3, 2022Business Services, Medical Communications
WHO have recommended Merck’s pill, molnupiravir, for the treatment of COVID-19 in patients in high risk groups, such as the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
